信迪利单抗治疗晚期实体恶性肿瘤的临床疗效分析  

Clinical Efficacy Analysis of Sintilimab in the Treatment of Advanced Solid Malignant Tumors

作　　者：衣素琴 严文跃 刘红旗 卞伟钢 YI Suqin;YAN Wenyue;LIU Hong qi;BIAN Weigang(Department of Oncology,Yancheng First People's Hospital,Yancheng,Jiangsu Province,224001 China)

机构地区：[1]盐城市第一人民医院肿瘤科,江苏盐城224001

出　　处：《中外医疗》2023年第36期78-81,共4页China & Foreign Medical Treatment

基　　金：江苏省卫生健康委科研课题(Z2018044)。

摘　　要：目的 分析信迪利单抗或甲磺酸阿帕替尼片单药治疗不能耐受或拒绝化放疗以及无合适靶向药物的晚期实体恶性肿瘤的临床疗效及不良反应。方法 回顾性选取2020年7月—2022年8月在盐城市第一人民医院就诊的91例不能耐受或拒绝化放疗以及无合适靶向药物的晚期实体恶性肿瘤患者的临床资料信息,根据不同的治疗方法将其分为两组,其中观察组46例,均予以信迪利单抗单药免疫治疗;对照组45例,均予以甲磺酸阿帕替尼片。所有患者经两个周期治疗后进行影像学评估疗效。结果 观察组的客观的缓解率(objectiveresponserate,ORR)为21.74%,疾病的控制率(diseasecontrolrate,DCR)为80.43%;对照组ORR是20.00%,DCR是71.11%,两组比较,差异无统计学意义(P均>0.05)。观察组与对照组不良反应均为1~2级,1级不良反应发生居多,总发生率分别为54.35%、75.55%,两组比较,差异有统计学意义(χ^(2)=4.487,P<0.05)。结论 对于不能耐受或拒绝化放疗以及无合适靶向药物的晚期肿瘤患者,信迪利单抗单药治疗较甲磺酸阿帕替尼片单药治疗疗效相当,但不良反应的发生率更低。Objective To analyze the clinical efficacy and adverse reactions of sintilimab or apatinib mesylate tablets as monotherapy for advanced solid malignant tumors that cannot tolerate or refuse chemoradiotherapy as well as those with no suitable targeted drugs.Methods The clinical data of 91 patients with advanced solid malignant tumors who could not tolerate or refused chemoradiotherapy and had no suitable targeted drugs who were admitted to Yancheng First People's Hospital from July 2020 to August 2022 were retrospectively selected,and the study was divided into two groups according to the different treatments.Among them,46 patients in the observation group were treated with sintilimab single-agent immunotherapy,and 45 patients in the control group were treated with apatinib mesylate tablets.After two cycles of treatment,all patients underwent imaging to evaluate the efficacy.Results The objective response rate(ORR) was 21.74% and the disease control rate(DCR) was 80.43% in the observation group.In the control group,the ORR was 20.00% and the DCR was 71.11%,there were no statistically significant differences between the two groups(both P>0.05).The occurrence of adverse reactions in the observation group and the control group were grade 1-2,with grade 1 adverse reactions occurring predominantly,and the total incidence rates were 54.35% and 75.55%,respectively,there was statistically significant difference in the incidence of adverse reactions between the two groups(χ^(2)=4.487,P<0.05).Conclusion For patients with advanced tumors who cannot tolerate or refuse chemora-diotherapy and who do not have suitable targeted drugs,sintilimab monotherapy has comparable efficacy to apatinib mesylate tablets monotherapy,but the incidence of adverse reactions is lower.

关 键 词：信迪利单抗 阿帕替尼 免疫治疗 靶向治疗 

分 类 号：R4[医药卫生—临床医学]